MTAI-1025 / Montai Therapeutics - LARVOL DELTA

Montai Therapeutics Presents Preclinical Data on NRF2 Agonist in Ulcerative Colitis at ACAAI Annual Meeting (Businesswire) - "Preclinical evaluations have indicated the candidate offers a highly promising profile to alleviate the inflammatory mechanisms of UC. Using a colitis mouse model, mice were treated over 14 days with MTAI-1025 (low, medium and high doses, oral daily), placebo, or an anti-IL-12p40 monoclonal antibody (mAb, 10 mg/kg, via intraperitoneal injection). MTAI-1025 elicited a clear dose-dependent reduction in key outcomes measures, such as the UC Disease Activity Index and weight loss, with better efficacy compared to the mAb. Analyses also revealed improved mucosal architecture and reduced inflammatory infiltration, with a marked reduction in pro-inflammatory cytokines, and confirmed NRF2 activation. Importantly, the tolerability profile was favorable with no signs of increased inflammation or necrosis."

Preclinical • Ulcerative Colitis